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Summary
Objective: Systematic review and meta-analysis of the most frequent treatment-
emergent central nervous system adverse events (CNS AEs) of new antiepileptic drugs
(AEDs) from double-blind, add-on, placebo-controlled studies conducted in adult
epileptic patients and identification of dose—adverse effect relationships.
Methods: Trial reports found by searching Medline and journals. Outcome was the
number of patients complaining of treatment-emergent CNS AEs. Sixteen predefined
CNS AEs were considered. Risk differences (RDs) were calculated for individual studies
and summary statistics estimated using the random effect model. Predefined CNS AEs
in patients treated with active drug (broken down into dose levels) or placebo were
extracted and the RDs (95% CI) for CNS AEs were calculated.
Results: Thirty-six suitable studies identified. No meta-analysis was possible for
oxcarbazepine and tiagabine (only one study each included). For these drugs RDs
were calculated from single studies.
Gabapentin was significantly associated with somnolence 0.13 (0.06—0.2) and
dizziness 0.11 (0.07—0.15); lamotrigine with dizziness 0.11 (0.05—0.17), ataxia
0.12 (0.01—0.24) and diplopia 0.12 (0.00—0.24); levetiracetam with somnolence
0.06 (0.01—0.11); pregabalin with somnolence 0.11 (0.07—0.15), dizziness
0.22 (0.16—0.28), ataxia 0.10 (0.06—0.14) and fatigue 0.04 (0.01—0.08); topir-
amate with somnolence 0.09 (0.04—0.14), dizziness 0.06 (0.00—0.11), cognitive
impairment 0.14 (0.06—0.22) and fatigue 0.06 (0.01—0.12); zonisamide with
somnolence 0.06 (0.02—0.11) and dizziness 0.06 (0.00—0.12). The dose—response
relationship was analysed only for those CNS AEs significantly associated with the
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Table 1 List of most important CNS AEs commonly
observed during treatment with antiepileptic drugs,
searched for in our analysis of double-blind studies
Affecting vigilance
Somnolence
Affecting the brain stem and vestibulocerebellar
system
Dizziness
Vertigo
Ataxia
Diplopia
Nystagmus
Affecting the motor system (extrapyramidal)
Chorea and dystonia
Parkinsonism
Tremor
Affecting cognition
Cognitive impairment
Psychiatric and psychological
Anxiety
Depression
Fatigue
Psychosis
Psychological and behavioural disturbances
Headache
Conclusions: No comparison between drugs was possible. One CNS AE was signifi-
cantly more frequent for levetiracetam, two for zonisamide and gabapentin, three
for lamotrigine and four for pregabalin and topiramate.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
In recent years, there has been an ever-increasing
number of new antiepileptic drugs (AEDs) from
which to choose as add-on drugs for people with
drug-resistant epilepsies. Although some differ-
ences in efficacy have recently been detected,1 it
has been suggested that, in this context, the selec-
tion of the appropriate AED should be largely influ-
enced by its tolerability profile.2
The analysis of double-blind studies offers a
unique opportunity to evaluate dose-dependent,
treatment-emergent adverse effects (AEs) because
in this case we can calculate the true incidence of a
particular AE by subtracting from the number of
patients complaining of an AE when treated with the
experimental drug, those patients who have the
same AE when treated with placebo. The odds ratios
of some frequently observed AEs have already been
calculated in two meta-analyses.3,4 Cramer et al.5,6
have calculated an overall measure of drug toler-
ability (summary complaint score) but quantitative
evaluations have not been done.
Up to now, a systematic analysis of all most
important adverse effects observed during treat-
ment with new AEDs has never been attempted
and in no case has the relation between the appear-
ance of an adverse effect and the dose of tested
drug been studied. In recent years, several double-
blind studies of new AEDs have been published.7—14
As far as we know, these studies have not been
included in the previous meta-analyses in which
adverse effects have been evaluated.
The aim of our study was to perform a quantita-
tive analysis of the most frequent adverse effects
(AEs) involving the CNS (CNS AEs) arising from treat-
ment with new AEDs from all double-blind, add-on,
clinical studies conducted in adults that have been
published up to now.
For all CNS AEs that were observed significantly
more frequently with the active drug, we also ana-
lysed the relation between dose of the experimental
drug and incidence of the AE.
We focused our analysis on eight new AEDs. These
were gabapentin (GBP), lamotrigine (LTG), levetir-
acetam (LEV), oxcarbazepine (OXC), pregabalin
(PGB), tiagabine (TGB), topiramate (TPM), and zoni-
samide (ZNS). We did not analyse studies conducted
with vigabatrin or felbamate because these drugs
may not be used as a first choice add-on drugs.Since a plethora of different adverse events is
reported in all studies, many of which bear no
relation to the active drug,5 an analysis of all of
these might be misleading. For this reason, we
identified a list of 16 adverse effects which we knew
were frequently observed in patients treated with
traditional and new AEDs15—17 and looked only for
these. These CNS AEs were divided into five broad
classes: those affecting vigilance, those affecting
the vestibulocerebellar system, those affecting the
motor system (including tremor), cognitive impair-
ment, and psychiatric and psychological adverse
effects (see Table 1).
Several problems will also be discussed in this
paper, that limit the information that can be drawn
from the analysis of double-blind studies.Methods
In October 2006, a computer search of Medline
(PubMed version) was conducted for all double-
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Table 2 Terms found in adverse reporting tables of the studies analysed which we considered synonymous with terms
included in our list
Terms included in our list Terms found in adverse effects reporting tables of various studies
Somnolence Drowsiness
Ataxia Abnormal gait
Tremor Slight tremor
Cognitive impairment Amnesia, aphasia, concentration impairment, confusion,
memory impairment, psychomotor slowing, speech
disorder, and abnormal thinking
Anxiety Emotional lability
Psychosis Dissociation and hallucination
Fatigue asthenia, tiredness, and general weakness
Psychological and behavioral disorders Hostility, nervousness, agitation, irritability, and insomniablind, placebo-controlled clinical studies concern-
ing GBP, LTG, LEV, PGB, OXC, TGB, TPM or ZNS. The
literature database was extracted using the follow-
ing Boolean keyword syntax: drug name AND epi-
lepsy AND double-blind study. This Medline search
produced 178 articles. After a careful analysis of
literature, a few further studies were added to this
list. From more than 180 articles, we selected the
trials that met each of the following criteria: R1
¼andomised controlled trials, double-blind versus
placebo, performed in patients with drug-resis-
tant partial or generalised epilepsies. Trials in which the experimental drug, or placebo,
had been added to a conventional AED treatment. Parallel or crossover design studies were included
but the minimum duration of each double blind
treatment had to be 8 weeks. Studies in which doses of associated drugs were
not changed during the experiment. Studies performed in adults. Studies performed in
special populations (children, patients with intel-
lectual disability, etc.) were excluded. Adverse effects had to be clearly reported in a
table in which the absolute number of each AE
was indicated or could be calculated (i.e.
reported as percentages). Two reviewers (GZ and PG) independently
assessed trials for inclusion. Any disagreements
were resolved by discussion.
Analysis and statistics
All analyseswere conducted according to intention-
to-treat principle and included all randomised par-
ticipants. For the analysis of adverse effects, we
considered it appropriate to perform a risk differ-
ence analysis1 (RD) instead of calculating the oddsCNS AE RD ðfor each CNS AEÞ
active drugpts:with SNC-AE
all pts treatedwith the active drug placebopts:with SNC-AEall pts treatedwith placebo.ratio (OR).18 While the OR indicates the increase in
risk of observing a specific AE (without any informa-
tion on the absolute risk of developing that AE), the
RD indicates the true incidence of the specific AE
(for example, what is the probability of developing
diplopia at the beginning of treatment with an
AED).
A first inspection revealed that only in some cases
did the AE reporting tables include all observed AEs.
More often, only those AEs whose frequency was
above a certain limit which was usually set between
5 and 10%, were reported.
For each AED, we proceeded as follows: first, we
selected all studies performed with the drug. From
the adverse effects reporting table of these studies,
we identified all CNS AEs that had been included in
our list (see Table 1). Then, for each study, the
number of patients complaining of each of the
selected CNS AEs and the number of treated
patients without the AE (total number of patients
treated with the experimental drug-patients com-
plaining of the analysed CNS AE) were extracted
both for patients randomised to active drug (also
broken down into all dose levels) and for those
randomised to placebo.
In some cases, in the adverse events reporting
tables the CNS AEs reported were defined in terms
that we considered synonymous with our previously
identified CNS AEs (for example drowsiness instead
of somnolence, abnormal gait instead of ataxia,
etc.). We decided to consider these terms as synon-
ymous and included these observations in our ana-
lysis. However, we did this only if only one of the
terms that we considered synonymous was used in
the study. If more than one term which we consid-
ered synonymous was used in a study (for example
asthenia and tiredness, which we consider synon-
ymous with fatigue), we only included the one most
frequently observed among patients treated with
the active drug. This was made to avoid the risk of
counting a single CNS AE observed in a patient more
408 G. Zaccara et al.than once. Table 2 states all the terms we consid-
ered synonymous.
For each CNS AE selected, we always included all
studies performed with an AED even though in some
studies no patients had been observed with that
particular CNS AE. This may have led to underesti-
mation of the true incidence of an AE because we
counted the number of patients with that AE as zero
in those studies even though a few patients might
have had that AE (under the percentage threshold
established in the adverse effect table).
In calculating the RD we included only those
patients treated with dose levels of the experimen-
tal drug lying within the range of doses recom-
mended by the Drug Information Monographs,
Clinical Pharmacology#, Version 6.09 (updated Sep-
tember 2006), Gold Standard, Tampa, FL (http://
cponline.hitchcock.org).
The RD for individual studies was calculated and
summary statistics estimated using the random
effect model. Statistical heterogeneity was checked
using a Chi-squared test for heterogeneity. In addi-
tion I2 was used to describe the percentage of total
variation across studies that was due to heteroge-
neity rather than chance.19
For those AEs that occurred significantly more
frequently among patients under treatment with
the experimental drug, we examined the dose—
response relationship using a Chi-square test for
trend with Mantel extension.20 This test calculates
the Chi-square, P value and odds ratio for each
exposure level compared with the first one (baseline
level) and analyses whether the odds calculated for
higher doses increase or not compared to baseline.
All these tests were done excluding placebo and
the smallest dose for each drug was considered as
the baseline exposure level. Since level 0 (placebo)
was not included in the calculation of trend, sig-
nificant data (which we set at P < 0.05) may be
considered a true expression of a dose—effect rela-
tionship.Results
Clinical material
Thirty-six studies satisfied our inclusion criteria and
entered our analysis. In all studies, AEs were calcu-
lated on the intention-to-treat population. The
total number of patients treated with active drugs
was 4403. Patients treated with placebo were 2243.
There were some differences in the numbers of
patients treated with experimental drugs (only 418
patients were treated with ZNS while almost 900
patients were treated with PGB) and placebo (from273 to 424 in studies with ZNS or LTG, respectively)
(see Table 3).
No details on how AEs were recorded were given
in 24 studies. In nine studies it was specified that AEs
had been ‘‘spontaneously reported’’ or reported
through a ‘‘non-directed’’ or ‘‘indirect’’ inquiry. In
two studies AEs were ‘‘solicited’’ and, in one study,
patients reported AE in a daily record card.
Results obtained for each drug are described
separately.
Gabapentin
We identified five double-blind studies (see Table 3).
The design of these studies was parallel in all cases.
Doses were always fixed, with a t.i.d. dosing
schema, and ranged from 600 to 1800 mg/day. Titra-
tion was fast (2—3 days) and length of the double-
blind phase was 12 weeks in all cases but one.
Maximum number of allowed concomitant AEDs
was set at two in all studies. The lower percentage
of AEs included in AE reporting tables was set
between 3 and 10%.
From our list of 16 CNS AEs we found seven CNS
AEs in patients included in studies with this drug
(ataxia, dizziness, diplopia, headache, nystagmus,
somnolence, and tremor) Two of these (somnolence
and dizziness) were significantly associated with
GBP (Fig. 1). The test for trend performed with
these two CNS AEs showed significant results only
for somnolence for doses of 600, 900, 1200, and
1800 mg/day (see Table 4).
Lamotrigine
The highest number of studies was identified for this
drug (nine studies). Almost all but one were rela-
tively small and had a crossover design (see Table 3).
In seven studies, doses were adjusted according to
the associated drug (inducer and/or inhibitor). Only
in two studies (one of them was the only one with a
parallel design) were doses fixed. Titration speed
was usually fast in line with the recommendations of
that time. In three studies titration speed was only 1
week. Duration of the double-blind phase was het-
erogeneous varying from 8 to 16 weeks. The baseline
for including AEs in reporting tables was set between
3 and 10% in six studies. Three reported all AEs.
Eleven previously defined CNS AE were found in
studies performed with this drug (ataxia, cognitive
impairment, depression, dizziness, diplopia, fati-
gue, headache, psychosis, somnolence, tremor,
and vertigo). Three (dizziness, ataxia, and diplopia)
reached statistical significance (see Fig. 2).
Although the analysis of trend was calculated from
only two studies (none of the other studies used
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Table 3 Characteristics of studies included in the analysis
Study No. of pts drug/
placebo and
model
No. of
concomitant
drugs
Daily dose (no. of pts treated
per dose)a/no. of administrations
Speed
titratio
Duration of double-
blind phase (weeks)
Lower frequency
limit of inclusion
of CNS AEs
GBP
US Gabapentin22 208/98, parallel 2 600 (53)—1200 (101)—
1800(54) mg/t.i.d.
2 or 3 ys 12 10%
Anhut et al. 23 163/109, parallel 2 900(111)—1200(52) mg/t.i.d. 2 days 12 >5%
Yamauchi et al. 13 127/82, parallel 2 1200(86)—1800(41) mg/t.i.d. 2 or 3 ys 12 >3%
Chadwick et al. 24 71/58, parallel 2 1200 mg/t.i.d. 2 week 14 3%
Sivenius et al. 21 25/18, parallel 2 900(16)—1200(9) mg/t.i.d. 2 days 12 10%
Total GBP 594/365
LEV
Betts et al.34, a 80/39, parallel 3 2000(42)—4000(38) mg/b.i.d. No tit 24 10%
Cereghino et al.36 199/95, parallel 2 1000(98)—3000(101) mg/b.i.d. 4 week 14 10%
Shorvon et al. 37 212/112, parallel 2 1000(106)—2000(106) mg/b.i.d. 2 week 12 5%
Ben-Menachem and Falter35 181/105, parallel 1 3000 mg/b.i.d. 4 week 18 5%
Tsai et al. 14 47/47, parallel 3 2000 mg/b.i.d. 2 week 14 5%
Total LEV 719/398
LTG
Sander et al. 27 21, crossover 3 100 or 200 mg/b.i.d. 2 week 12 (each treatment) All AE
Schapel et al. 29 41, crossover 2 150 or 300 mg/b.i.d 1 week 12 (each treatment) All AE
Loiseau et al. 26 25, crossover 2 150 or 300 mg/b.i.d 1 week 8 (each treatment) All AE
Boas et al. 32 56, crossover 3 75—400 mg/b.i.d 1 week 12 (each treatment) 10%
Smith et al. 30 81, crossover 2 200—400 mg/b.i.d 2 week 16 (each treatment) 3%
Jawad et al.25 24, crossover 2 75—400 mg/b.i.d 4 week 12 (each treatment) 5%
Matsuo et al.28 143/73, parallel 3 300(71)—500(72) mg/b.i.d 4 week 24 10%
Messenheimer et al. 31 98, crossover 2 400 mg/b.i.d 3 week 14 (each treatment) 10%
Beran et al. 33 26, crossover 4 75 or 150 mg/b.i.d 3 week 8 (each treatment) 8%
Total LTG 494/424
OXC
Barcs et al. 38 519/173, parallel 3 600(168)—1200(177)—
2400(174) mg/b.i.d.
2 week 26 10%
Total OXC 519/173of
n
da
da
s
s
s
s
s
s
s
s
s
s
s
s
410
G
.
Z
accara
e
t
al.
Table 3 (Continued )
Study No. of pts drug/
placebo and
model
No. of
concomitant
drugs
Daily dose (no. of pts treated
per dose)a/no. of administrations
Speed of
titration
Duration of double-
blind phase (weeks)
Lower frequency
limit of inclusion
of CNS AEs
PGB
French et al.8 265/100, parallel 3 50(88)—150(86)—300(90)—
600(89) mg/b.i.d.
No tit 12 10%
Beydoun et al. 10 214/98, parallel 3 600 mg/b.i.d. or t.i.d. 8 days 12 10%
Arroyo et al. 9 191/97, parallel 3 150(99)—600(92) mg/t.i.d. 4 or 8 days 12 10%
Elger et al. 12 268/73, parallel 3 600(137) or flexible 150 to
600(131) mg b.i.d
No tit or 8 days 12 10%
Total PGB 938/368
TGB
Kalviainen et al.39 77/77, parallel 3 30 mg/t.i.d. 4 weeks 22 5%
Total TGB 77/77
TPM
Faught et al. 41 135/45, parallel 2 200(45)—400(45)—
600(45) mg/b.i.d.
4 weeks 16 20%
Guberman et al. 7 171/92, parallel 2 200 mg/b.i.d. 4 or 8 weeks 16 5%
Sharief et al. 43 23/24, parallel 2 400 mg/b.i.d. 3 weeks 11 10%
Korean TPM Group45 91/86, parallel 2 600 mg/b.i.d. 10 weeks 18 5%
Tassinari et al. 44 30/30, parallel 2 600 mg/b.i.d. 4 weeks 12 10%
Privitera et al. 42 143/47, parallel 2 600(48)—800(48)—
1000(47) mg/b.i.d.
6 weeks 18 20%
Yen et al.46 23/23, parallel 4 300 mg/b.i.d. 6 weeks 14 5%
Ben-Menachem et al. 40 28/18, parallel 2 800 mg/b.i.d. 5 weeks 13 15%
Total TPM 644/365
ZNS
Brodie et al. 11 229/120, parallel 4 100(56)—300(55)—
500(118) mg/b.i.d.
6 weeks 24 10%
Faught et al. 48 118/85, parallel 2 400 mg/b.i.d. 8 weeks
different
speeds
20 10%
Schmidt et al. 47 71/68, parallel 3 6 mg/Kg. up to 20 mg/kg/b.i.d 4 weeks 12 5%
Total ZNS 418/273
a In parentheses is reported the number of patients treated with the experimental dose (only indicated in parallel studies in which different doses were administered).
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Figure 1 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with gabapentin.
Figure 2 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with lamotrigine.
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Figure 3 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with levetiracetam.
Table 4 Results of analysis of dose-effect relationship (trend analysis) for CNS AEs occurring significantly more
frequently during treatment with gabapentin
No. of studies No. of doses x2 trend p(x2) trend
Somnolence 5/5 4 8.21 0.004
Dizziness 5/5 4 0.22 0.64
No. of studies: number of studies included in this analysis/total number of studies; no. of doses: number of dose levels used in the
analysis (for details see text).fixed doses) and only with three different dose
levels (300, 400, and 500 mg/day), all three CNS
AEs were found dose-related (Table 5).
Levetiracetam
We identified five double-blind studies (see Table 3)
performed with this drug in adult patients. The
design of these studies was parallel in all cases.
Doses studied were 1000, 2000, 3000, and 4000 mg/
day, always with a b.i.d. dosing schema. Titration
was usually performed in 2—4 weeks and in one
study there was no titration. Duration of the dou-
ble-blind phase ranged from 12 to 24 weeks. Max-
imum number of allowed concomitant AEDs was two
in two studies, one in one study and up to three in
the last. The lower percentage of AEs included in AE
reporting tables was set between 5 and 10%. Since
4000 mg/day is not a recommended dosage (see
above), patients treated with this dosage were
excluded from the calculation of RD.
Six of the previously defined CNS AEs were found
in patients treated with this drug: depression, diplo-Table 5 Results of the analysis of dose-effect relationship f
treatment with lamotrigine (see legend of Table 4)
No. of studies No. of
Dizziness 2/9 3
Ataxia 2/9 3
Diplopia 2/9 3
Only studies that used fixed doses were included in this analysis.pia, dizziness, fatigue, headache, and somnolence.
Only somnolence was significantly associated with
LEV (Fig. 3). The test for trend, performed on doses
from 1000 to 4000 mg/day, failed to show a relation
between somnolence and drug dose (Table 6).
Oxcarbazepine
Only one large, add-on double-blind study (see
Table 3) with a parallel design has been performed
with this drug in adult patients. Drug doses adminis-
tered were 600, 1200 and 2400 mg/day, always with
a b.i.d. dosing schema. Titration speed was 2 weeks
and total duration of double-blind phase was 26
weeks. Maximum number of allowed concomitant
AEDs was up to a maximum of three.
The threshold for AEs included in the AE reporting
table was 10%.
We could not perform a meta-analysis for this
drug. RD analysis from data of the only study avail-
able has been done. Nine of our predefined CNS AEs
were found in patients recruited to this study:
ataxia, diplopia dizziness, fatigue, headache, nys-or CNS AEs occurring significantly more frequently during
doses x2 trend p(x2) trend
8.17 0.004
6.20 0.012
10.6 <0.001
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Table 7 Risk difference values of CNS AEs observed in
patients treated with OXC in the study of Barcs et al.38
CNS AE RD 95% CI
Somnolence 0.15 0.09—0.21
Dizziness 0.20 0.14—0.27
Vertigo 0.08 0.05—0.12
Ataxia 0.15 0.10—0.19
Diplopia 0.23 0.18—0.28
Nystagmus 0.13 0.09—0.17
Tremor 0.05 0.01—0.08
Fatigue 0.07 0.02—0.12
Only those CNS AEs defined in our list.
Table 6 Results of the analysis of dose-effect rela-
tionship for CNS AEs occurring significantly more fre-
quently during treatment with levetiracetam (see
legend of Table 4)
Somnolence
No. of studies 5/5
No. of doses 4
x2 trend 2.24
p(x2) trend 0.13tagmus, somnolence, tremor and vertigo. All of
these CNS AE except headache were significantly
more frequent in patients treated with the experi-
mental drug (see Table 7) and all but fatigue were
clearly dose-related (Table 8).
Pregabalin
Four, recently published, large, double-blind, add-
on, parallel studies (see Table 3) were found with
this drug. Doses were 50, 150, 300 and 600 mg/day.
In a subgroup of the last study12 patients were
treated with flexible doses of the drug. In this group
of patients, the drug was started at a dose of
150 mg/day and increased to 300 mg/day. Further
increases to a maximum dose of 600 mg/day were
made only in those patients who experienced sei-
zures. Titration was varied from no titration up to 1Table 8 Results of the analysis of dose-effect relationship f
treatment with oxcarbazepine (see legend of Table 4)
No. of studies No. o
Somnolence 1/1 3
Dizziness 1/1 3
Vertigo 1/1 3
Ataxia 1/1 3
Diplopia 1/1 3
Nystagmus 1/1 3
Tremor 1/1 3
Fatigue 1/1 3week. Dosing schemewas b.i.d. in two studies, t.i.d.
in one and one study had patients randomised to
b.i.d. or t.i.d. treatments. Maximum number of
allowed concomitant AEDs was set at a maximum
of three in all studies. Threshold of AEs included in
AE reporting tables was always 10%. We excluded
the subgroup of patients treated with 50 mg/day
from meta-analysis because this dose is not clini-
cally effective.
From our list, we identified nine CNS AEs in
patients treated with this drug. These were
ataxia, cognitive impairment, diplopia, dizziness,
fatigue, headache, somnolence, tremor, and ver-
tigo. Somnolence, dizziness, ataxia and fatigue
were significantly associated with PGB (see
Fig. 4). Test for trend was performed on three
different dose levels (150, 300, and 600 mg/
day). In this analysis, the subgroup of patients
treated with flexible doses of drug12 were
excluded. All significant CNS AEs but fatigue were
dose-related (see Table 9).
Tiagabine
Only one study (see Table 3) performed with this
drug in adults has been included in our analysis. This
study had a parallel design with a fixed dose of
30 mg/day, a titration speed of 4 weeks and duration
of double-blind phase 22 weeks. Maximum number
of allowed concomitant AEDs was up to a maximum
of three.We excluded two large studies49,50 because
adverse effect reporting tables in these studies
included only a selected number of AEs, i.e. those
significantly more frequent. This precluded any
possible meta-analysis.
From our list, we identified eight CNS AEs in
patients treated with this drug. These were cogni-
tive impairment, dizziness, diplopia, fatigue, head-
ache, psychological and psychiatric disturbance,
somnolence, and tremor. Dizziness (RD = 0.18, 95%
CI 0.06—0.3) and cognitive impairment (RD = 0.06;
95% CI = 0.01—0.12) were significantly associated
with TGB. Dose-effect relationship could not beor CNS AEs occurring significantly more frequently during
f doses x2 trend p(x2) trend
6.35 0.011
12.07 <0.001
4.22 0.04
28.4 <0.001
24.32 <0.001
14.49 <0.001
12.68 <0.001
0.04 0.84
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Figure 4 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with pregabalin.calculated because only one dose level (30 mg/day)
was available.
Topiramate
Eight double-blind studies (see Table 3) were done
with this drug in adults. All had a parallel design.
Doses, administered with a b.i.d. dosing schema,
were 200, 300, 400, 600, 800, and 1000 mg/day.
Titration was generally faster (3—4 weeks) in older
studies than in more recent ones (6—10 weeks). In
one study7 different speeds of titration were used (4
or 8 weeks). Duration of the double-blind phase
ranged from 11 to 18 weeks. Maximum number of
allowed concomitant AEDs was two in all studies butTable 9 Results of the analysis of dose-effect relationship f
treatment with pregabalin (see legend of Table 4)
No. of studies No. o
Somnolence 4/4 3
Dizziness 4/4 3
Ataxia 4/4 3
Fatigue 4/4 3one46 in which up to four drugs were allowed.
Thresholds for inclusion in AE reporting tables were
5% or10% in five studies while in one it was15%
and in two 20%. This may have caused a selection
bias due to a reduction in the number of CNS AEs
associated with the drug.
Eleven of the previously defined CNS AEs were
identified in studies conducted with this drug. These
were anxiety, ataxia, cognitive impairment, depres-
sion, diplopia, dizziness, fatigue, headache, nystag-
mus, psychological and behavioural disturbances,
and somnolence.
For this drug we observed that several CNS AEs
were reported using many different terms (see
Table 2) that could be considered as synonymousor CNS AEs occurring significantly more frequently during
f doses x2 trend p(x2) trend
15.86 <0.001
24.17 <0.001
22.23 <0.001
1.21 0.27
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Figure 5 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with topiramate.with cognitive impairment. So in this case, from
those studies in which more than one of these
CNS AEs had been observed, we included only
the most frequent. This is a very conservative
approach that allowed us to be sure that in no
case could we have counted a patient more thanTable 10 Results of the analysis of dose—effect relations
during treatment with topiramate (see legend of Table 4)
No. of studies No.
Somnolence 8/8 6
Dizziness 8/8 6
Impaired conc 8/8 6
Fatigue 5/8 5once who had had more than one of these cogni-
tive adverse events.
Somnolence, dizziness, fatigue and cognitive
impairment were significantly more frequently asso-
ciated with the experimental drug (Fig. 5). Test for
trend (see Table 10), was performed on five differ-hip for CNS AEs occurring significantly more frequently
of doses x2 trend p(x2) trend
3.39 0.65
24.13 <0.001
33.7 <0.001
27.87 <0.001
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Figure 6 Risk difference (95% CI) of those CNS adverse effects which were significantly (P < 0.05) more frequent under
treatment with zonisamide.
Table 11 Results of the analysis of dose—effect relationship for CNS AEs occurring significantly more frequently
during treatment with zonisamide (see legend of Table 4)
No. of studies No. of doses x2 trend p(x2) trend
Somnolence 3/3 4 4.96 0.025
Dizziness 3/3 4 5.27 0.02ent dose levels (from 200 to 1000 mg/day). A dose—
effect relation was shown only for dizziness, cogni-
tive impairment and fatigue.
Zonisamide
Three double-blind parallel studies (see Table 3)
were found with this drug in adults. In all studies a
b.i.d. dosing scheme was adopted. In two studies
the doses tested were 100, 300, 400, and 500 mg/
day. In the third study47 doses were adjusted,
according to clinical response, up to 20 mg/
(kg day) using information derived from drug
levels.
Titration speed was between 4 and 8 weeks.
Duration of double-blind phase ranged between
12 and 24 weeks. Maximum number of allowed
concomitant AEDs was up to two, three or four drugs
according to different studies. Threshold of AEs
included in reporting tables were set between 5
and 10%.
Ataxia, dizziness, fatigue, headache, psychologi-
cal and behavioural disturbances and somnolence
were found in patients treatedwith the drug. Among
these CNS AEs, dizziness and somnolence were sig-
nificantly associated with ZNS (Fig. 6). Test for trend
which was performed on data from the two studies
that used fixed doses, and used all 4 dose levels
studied, found a dose—effect relation for both CNS
AEs (Table 11).Discussion
Several methodological problems encountered in
performing this meta-analysis of treatment-emer-
gent CNS AEs from double-blind studies need to be
carefully discussed.
Need to set limits on AEs
In clinical studies a plethora of adverse events is
reported that are often unrelated to the active
drug. They are also observed in patients treated
with placebo.5 For statistical reasons, it is impos-
sible to try to identify a possible relation between
the experimental drug and all the adverse events
observed. To overcome this problem, we focused
our attention on a limited number of predefined CNS
AEs that we knew from the literature15—17 are fre-
quently observed during treatment with new and/or
traditional AEDs and looked only for these.
Differently defined AEs
We found that several CNS AEs may be defined
differently (for example ataxia and uncoordinated
gait). We considered some terms to be synonymous
with CNS AEs included in our list (for example,
drowsiness was considered synonymous with som-
nolence). In Table 2 we report all terms that we
accepted as synonymous for terms included in our
CNS AEs of new antiepileptic drugs 417predefined list. However, it was not always clear
whether these terms were synonymous or indicated
similar but different CNS AEs. Moreover, when two
terms that we considered as synonymous appeared
in the same study, we could not be absolutely sure
that these adverse events were always observed in
different patients or, in a certain percentage of
cases, in the same patient. A particular case was
cognitive effects of TPM. For this drug, some authors
used the term ‘‘abnormal thinking’’ which probably
included several cognitive effects induced by the
drug. In other studies several different terms were
used (see Table 2). Therefore this is a special case in
which we do not know if some of these AEs were
always observed in different patients or, in some
cases, in the same patient. For this reason, we
adopted a conservative strategy. We never included
two possible synonymous of the same AE from the
same study. This was done to be sure to avoid
counting a patient twice for similar adverse effects.
In the case of two similar terms present in the same
study, we always selected the most frequent, and
neglected the less frequent. This procedure wea-
kened the power of detection of CNS AEs but
reduced the possibility of bias selection.
Limited information from clinical studies
The total number of AEs was reported only in three
small studies with LTG. In all other studies, only
those AEs above a certain percentage were
reported. This precludes the possibility of analysing
relatively infrequent AEs. The lower limit for includ-
ing an AE in the respective tables was set between
3 and 10% in 30 studies. However, two studies
performed with TPM reported only those AEs more
frequent than 20% and one study with the same
drug, only those more frequent than 15%. This limit
may have excluded some AEs and improved the
tolerability profile of the drug which emerges from
our analysis. Finally, with TGB two of the three key
clinical studies49,50 included only AEs significantly
more frequent with the active drug. For this reason,
these studies were excluded and a meta-analysis
could not be done for this drug.
Severity
No information is available on the severity of
reported CNS AEs.
Number of clinical studies and total
number of patients recruited
A high number of small clinical studies performed
with a drugmay lead to increased heterogeneity andmake the attainment of statistical significance more
difficult (random effect model instead of fixed
model analysis).18 Examples are OXC on one hand
and LTG and TPM on the other. While only one large
study on adults was performed for OXC,38 LTG and
TPM had several studies (nine and eight, respec-
tively, see Table 3) and, because of possible differ-
ences (different words to define similar AEs,
different percentages of AE due to different designs
of study, etc.) there was an high degree of hetero-
geneity which led to much more conservative sta-
tistical evaluations.18 For this reason, data obtained
with OXC and TGB cannot be comparedwith those of
other AEDs. Finally, the total number of patients
recruited for treatment with these drugs was very
different (from 418 for ZNS to almost 900 for PGB).
These differences might have advantaged drugs
studied with smaller numbers of patients (ZNS).
Characteristics of clinical studies which
may have influenced drug tolerability(a) Dose: It is obvious that dose is a critical factor in
the determination of treatment-emergent CNS
AEs. Different drugs have been studied with
dose ranges that are not identical and not
necessarily in the same proportion (it is possible
that more patients were treated with high doses
of an experimental drug compared with the
number of patients treated with high doses of
another experimental drug).(b) Speed of titration: For some drugs, particularly
TPM51 and LTG,52 tolerability is strongly influ-
enced by titration speed. For other drugs, this
factor seems to be less critical even though we
cannot be sure for example that PGB tolerability
would have been better with slower titrations
than those used in clinical studies. However,
titration speeds higher than those recom-
mended were used in some trials (for example
trials with LTG, TPM, and PGB).(c) Number of administrations: For some drugs with
a short half-life (GBP and TGB), the number of
daily administrations may affect the probability
of the appearance of CNS AEs that correlate
with fluctuations of blood levels. In fact, in
some trials, in an effort to observe possible
differences in respect to tolerability, subjects
were randomised to different numbers of daily
administrations.49,10 We did not analyse these
groups of patients separately. However, from an
inspection of the AE profile observed in these
studies, we think that this factor is much less
important than dose and titration speed.(d) Duration of the study: The length of a study
should be sufficient to allow the most frequent
418 G. Zaccara et al.AEs to appear. Durations of the studies were
very heterogeneous (range from 8 to 26 weeks)
so that the spectrum of the observed AEs may
have been affected by the duration of studies.
However, we think that vast majority of CNS AEs
do appear soon after the beginning of treatment
or a dose increase.In the attempt to reduce the risk of identifyingCNS
AEs incorrectly, we adopted a very conservative
approach. Firstly, when different CNS AEs defined
in terms that we considered synonymous were pre-
sent in a study we always counted the most frequent
and neglected the other(s). Secondly, when calculat-
ing the risk difference of a single CNS AE we always
included all studies. This means that for the evalua-
tion of an adverse effect, studies were also included
in the analysis in which no patients with that AE had
been observed (see Figs. 1—6). As a consequence, for
several less frequentAEs thatwerenotobserved inall
studies, a statistically significant difference may
have not been reached. A third important considera-
tion is that, since there was a high degree of hetero-
geneity between clinical studies and high I2 values,
wehad toadopt randommodel analysiswhich ismuch
more conservative than fixed model analysis.
All these considerations indicate that from these
data we cannot have an exhaustive picture of all CNS
AEs and that we cannot make a comparison of CNS
AEs between drugs. However, this systematic ana-
lysis of clinical studies, which is inevitably limited to
the most frequent treatment-emergent CNS AEs,
gives us the best possible evidence of a causal
relation between the most important, treatment-
emergent tolerability problems and new AEDs. We
were also able to demonstrate a dose relation for
several of them. This finding, when present, further
strengthens the causal relation between the CNS AE
and the responsible AED.
We divided CNS AEs into six different classes
because we think that this may make discussion
of our results clearer.(1) Somnolence is the most frequently observed
neurological AE with traditional AEDs15 and sev-
eral new AEDs still cause this adverse effect.(2) Vestibulocerebellar CNS AEs. It is well known
that traditional AEDs, mainly phenytoin and
carbamazepine, at high doses, may cause brain
stem and/or cerebellar dysfunction, resulting in
disorders of upright stance and gait (ataxia,
poor coordination, dizziness, and vertigo) and
ocular motricity (diplopia, oscillopsia, and nys-
tagmus)17. We considered dizziness, vertigo,
ataxia, diplopia and nystagmus as vestibulocer-
ebellar AEs. In particular, we hypothesize thatdizziness may be considered a first sign of ves-
tibulocerebellar involvement.17(3) Cognitive impairment is a feared consequence
of some AEDs treatments.53 We decided to con-
sider all AEs affecting cognition as a single CNS
AE because we thought that information was not
enough detailed in all clinical studies to allow
for a more precise evaluation.(4) CNS AEs affecting motor system. Traditional
AEDs have been associated with several symp-
toms of motor system abnormalities (chorea,
parkinsonism, dyskinesia, etc.), particularly
tremor.17(5) Psychiatric CNS AEs. Several studies indicate
that depression, psychosis and several beha-
vioural and psychological disturbances may be
related to AED therapy.54 We included fatigue in
this class of CNS AEs. It is known that fatigue
may be a symptom of several diseases which
affect the CNS. It may be caused by interference
with several neurotransmitter systems, particu-
larly serotonin.55(6) Finally, headache is one of the most frequently
signalled CNS AEs in clinical trials.CNS AEs found with different AEDs
Gabapentin
Two CNS AEs were significantly associated with this
drug, somnolence and dizziness. Only somnolence
showed a correlation with dose. Results of this
meta-analysis confirm that this drug is sedative
and has some effect on vestibulocerebellar func-
tions. Since ataxia and diplopia were not significant,
this effect on vestibulocerebellar functions should
be weak. A possible explanation for lack of correla-
tion between the dose and the dizziness could be the
nonlinear absorption kinetics of this drug.56
Lamotrigine
Our data indicate that this drug affects mainly
vestibulocerebellar function since dizziness, ataxia,
and diplopia were significantly more frequent in
patients treated with this drug. All these effects
were dose-related. In contrast, LTG does not have
sedative properties since this meta-analysis did not
demonstrate a significant association between LTG
and somnolence (which remains the most frequent
CNS AE even with new AEDs).
Levetiracetam
Somnolence was the only CNS AE significantly asso-
ciated with this drug. It is interesting to note that we
found a clear lack of relation between this CNS AE
and dose. In fact, the highest percentage of patients
with this CNS AE was found in the study of Tsai
CNS AEs of new antiepileptic drugs 419et al.14 in which a relatively low dose of drug
(2000 mg/day) was administered. We can speculate
that a small percentage of patients may show a
special sensitivity to this CNS AE even at low doses.
Oxcarbazepine
We did not perform a meta-analysis for this AED
since only one study with a population of adult
epileptic patients had been published.38 However,
results of our RD analysis show that all vestibulocer-
ebellar CNS AEs (dizziness, vertigo, ataxia, diplopia,
and nystagmus) are significantly correlated with
treatment with this drug. Significant results for
somnolence indicate that OXC has also sedative
properties. OXC is also significantly associated with
tremor. We do not know if in this case this symptom
is in some way related to cerebellar dysfunction. All
these CNS AEs were strongly dose-related. Fatigue,
the last CNS AE significantly associated with drug,
was not dose-related. When considering these
results we should remember that in the study by
Barcs et al.38, after a relatively short titration, some
patients were treated with 2400 mg/day of drug.
For reasons linked to study design and statistics we
cannot compare OXC and other AEDs.
Pregabalin
PGB has amechanism of action similar to that of GBP
and its tolerability spectrum also seems to be simi-
lar. This drug has sedative properties (somnolence
significantly more frequent in patients treated with
active drug) and an effect on vestibulocerebellar
functions demonstrated by dizziness and also
ataxia. Finally, fatigue was also associated with
the drug although not dose-related.
Tiagabine
For this drug, only one clinical trial was included in
our study. This precluded a meta-analysis. Further-
more, since this study only recruited a small number
of patients, the RD analysis was of low statistical
power. However, dizziness and cognitive impairment
were found to be significantly associated with the
drug. No dose—effect relationship could be done,
since in this case, only one dose level was available.
The clinical meaning of this finding is questionable.
Other CNS AEs (tremor, depression, psychological
and behavioural disorders) were found to be signifi-
cantly associated with this drug in clinical stu-
dies49,50 that were not analysed.
Topiramate
This drug causes sedation and has weak effects on
vestibulocerebellar structures as is testified by it
being significantly associated with dizziness. Fati-
gue was also significantly associated with this drug.A particular aspect of tolerability of TPM is that this
drug may cause cognitive impairment. We included
all CNS AEs affecting cognition under this term. This
CNS AE was clearly dose dependent and indicates a
selective spectrum of toxicity typical of the drug. A
detailed description of this aspect of tolerability of
TPM cannot be derived from the analysis of clinical
studies.
Zonisamide
This drug was significantly associated only with som-
nolence and dizziness indicating sedative effects and
a mild effect on vestibulocerebellar function.
In conclusion, the analysis of double-blind, pla-
cebo controlled studies is certainly the most robust
way to identify a causal relationship between treat-
ment with new AEDs and some frequently observed,
treatment-emergent CNS AEs in relatively homoge-
neous populations of drug-resistant epileptic
patients. We are aware that we performed six dif-
ferent meta-analyses and that no comparisons
between drugs can be made. However, some cau-
tious comment may be made. As regards CNS AEs,
new AEDs seem to have different toxicological pro-
files. All new AEDs except LTG and TGB (but no
meta-analysis could be performed with this last
drug) have sedative properties. Brain stem and
cerebellar functions are mildly affected by GBP,
TPM, ZNS and, probably, TGB, which were found
significantly associated only with dizziness, and
more heavily affected by LTG, PGB, OXC for which
also other vestibulocerebellar CNS AEs were found
(diplopia, ataxia, etc.). In no cases did we demon-
strate association with important motor AEs or psy-
chiatric and psychological disturbances. Tremor was
caused by OXC but we know that this adverse effect
has also been found with TGB in studies which we
excluded from our analysis.50 We think that the
pathogenetic mechanism of this symptom might
be different with these two drugs. Finally, headache
was frequently signalled as a CNS AE but the RD
analysis (data not shown) often revealed a trend,
always non-significant, in favour of a possible pro-
tective effect of the experimental drug.
Finally, we noted that LEV was significantly asso-
ciated only with one CNS AE, ZNS and GBP were
associated with two, LTG was associated with three
and both PGB and TPM with four CNS AEs.Acknowledgements
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